Cutler Group’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,100
| Closed | -$5K | – | 6529 |
|
|
2021
Q3 | $5K | Hold |
1,100
| – | – | ﹤0.01% | 4537 |
|
|
2021
Q2 | $5K | Buy |
1,100
+100
| +10% | +$518 | ﹤0.01% | 4528 |
|
|
2021
Q1 | $4K | Sell |
1,000
-200
| -17% | -$1.04K | ﹤0.01% | 4612 |
|
|
2020
Q4 | $5K | Hold |
1,200
| – | – | ﹤0.01% | 3732 |
|
|
2020
Q3 | $4K | Sell |
1,200
-600
| -33% | -$2.32K | ﹤0.01% | 3756 |
|
|
2020
Q2 | $4K | Hold |
1,800
| – | – | ﹤0.01% | 3536 |
|
|
2020
Q1 | $5K | Sell |
1,800
-849
| -32% | -$3.81K | ﹤0.01% | 3132 |
|
|
2019
Q4 | $10K | Buy |
2,649
+600
| +29% | +$2.87K | ﹤0.01% | 2676 |
|
|
2019
Q3 | $10K | Hold |
2,049
| – | – | ﹤0.01% | 2653 |
|
|
2019
Q2 | $12K | Hold |
2,049
| – | – | ﹤0.01% | 2582 |
|
|
2019
Q1 | $14K | Sell |
2,049
-300
| -13% | -$2.7K | ﹤0.01% | 2302 |
|
|
2018
Q4 | $20K | Sell |
2,349
-700
| -23% | -$9.1K | ﹤0.01% | 2130 |
|
|
2018
Q3 | $61K | Buy |
3,049
+500
| +20% | +$11.7K | ﹤0.01% | 1490 |
|
|
2018
Q2 | $65K | Buy |
+2,549
| New | +$70.6K | 0.01% | 1441 |
|
|
2018
Q1 | – | Sell |
-100
| Closed | -$3.15K | – | 5563 |
|
|
2017
Q4 | $3K | Sell |
100
-409
| -80% | -$11.4K | ﹤0.01% | 4040 |
|
|
2017
Q3 | $10K | Buy |
+509
| New | +$9.33K | ﹤0.01% | 3842 |
|
|
2016
Q4 | – | Sell |
-7,600
| Closed | -$118K | – | 7621 |
|
|
2016
Q3 | $124K | Sell |
7,600
-1,945
| -20% | -$29.6K | 0.01% | 1633 |
|
|
2016
Q2 | $144K | Buy |
+9,545
| New | +$157K | 0.01% | 1373 |
|
Cutler Group's ADMS Position: Q4 2021 in Review
Cutler Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 1,100 shares — an estimated $5K sold.
Cutler Group first reported a position in ADMS in Q2 2016 and held it in 18 quarters. The position peaked at $144K in Q2 2016. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Cutler Group reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Cutler Group sold 1,100 Adamas Pharmaceuticals shares in Q4 2021, an estimated $5K.
- Cutler Group first reported a position in Adamas Pharmaceuticals in Q2 2016 and held it in 18 quarters.
- Cutler Group's Adamas Pharmaceuticals position peaked at $144K in Q2 2016.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.